Cibc Asset Management Inc Neurocrine Biosciences Inc Transaction History

Cibc Asset Management Inc

  • $27.8 Billion
  • Q1 2025

A detailed history of Cibc Asset Management Inc transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Cibc Asset Management Inc holds 4,288 shares of NBIX stock, worth $535,013. This represents 0.0% of its overall portfolio holdings.

Number of Shares
4,288
Previous 4,078 5.15%
Holding current value
$535,013
Previous $556,000 14.75%
% of portfolio
0.0%
Previous 0.0%

Shares

22 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 13, 2025
BUY
$107.22 - $153.29 $22,516 - $32,190
210 Added 5.15%
4,288 $474,000
Q4 2024

Jan 31, 2025
BUY
$111.62 - $139.44 $54,358 - $67,907
487 Added 13.56%
4,078 $556,000
Q3 2024

Nov 06, 2024
BUY
$114.58 - $153.15 $21,884 - $29,251
191 Added 5.62%
3,591 $413,000
Q2 2024

Aug 01, 2024
BUY
$130.86 - $143.19 $20,021 - $21,908
153 Added 4.71%
3,400 $468,000
Q1 2024

May 09, 2024
BUY
$130.4 - $143.74 $912 - $1,006
7 Added 0.22%
3,247 $447,000
Q4 2023

Feb 13, 2024
SELL
$106.07 - $132.76 $24,290 - $30,402
-229 Reduced 6.6%
3,240 $426,000
Q3 2023

Oct 30, 2023
BUY
$94.02 - $117.1 $4,512 - $5,620
48 Added 1.4%
3,469 $390,000
Q2 2023

Aug 14, 2023
BUY
$89.53 - $104.87 $268 - $314
3 Added 0.09%
3,421 $322,000
Q1 2023

May 12, 2023
BUY
$94.11 - $123.02 $30,585 - $39,981
325 Added 10.51%
3,418 $345,000
Q4 2022

Feb 13, 2023
SELL
$106.72 - $127.06 $124,115 - $147,770
-1,163 Reduced 27.33%
3,093 $369,000
Q3 2022

Nov 03, 2022
BUY
$92.03 - $107.81 $1,104 - $1,293
12 Added 0.28%
4,256 $452,000
Q2 2022

Aug 09, 2022
SELL
$75.79 - $100.07 $4,471 - $5,904
-59 Reduced 1.37%
4,244 $414,000
Q1 2022

May 06, 2022
BUY
$72.45 - $94.81 $1,738 - $2,275
24 Added 0.56%
4,303 $403,000
Q4 2021

Feb 08, 2022
BUY
$79.65 - $106.22 $33,691 - $44,931
423 Added 10.97%
4,279 $364,000
Q3 2021

Nov 09, 2021
BUY
$86.18 - $99.03 $29,128 - $33,472
338 Added 9.61%
3,856 $370,000
Q2 2021

Aug 16, 2021
BUY
$89.43 - $102.27 $536 - $613
6 Added 0.17%
3,518 $342,000
Q1 2021

May 14, 2021
SELL
$87.57 - $119.4 $939,976 - $1.28 Million
-10,734 Reduced 75.35%
3,512 $342,000
Q4 2020

Feb 03, 2021
BUY
$86.91 - $108.33 $71,092 - $88,613
818 Added 6.09%
14,246 $1.37 Million
Q3 2020

Nov 05, 2020
BUY
$96.16 - $135.15 $966,696 - $1.36 Million
10,053 Added 297.87%
13,428 $1.29 Million
Q4 2019

Feb 14, 2020
BUY
$86.8 - $118.57 $16,839 - $23,002
194 Added 6.1%
3,375 $363,000
Q2 2018

Aug 09, 2018
BUY
$75.3 - $105.99 $16,189 - $22,787
215 Added 7.25%
3,181 $313,000
Q4 2017

Feb 02, 2018
BUY
$58.53 - $77.59 $173,599 - $230,131
2,966
2,966 $230,000

Others Institutions Holding NBIX

# of Institutions
649
Shares Held
97.1M
Call Options Held
749K
Put Options Held
553K
View Full List

About NEUROCRINE BIOSCIENCES INC

NBIX Quotes by TradingView
  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $11.9B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Cibc Asset Management Inc Portfolio

Follow Cibc Asset Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cibc Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Cibc Asset Management Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email